vidutolimod by Regeneron Pharmaceuticals — Product Research | aVenture Research
Vidutolimod (CMP-001) is an investigational Toll-like receptor 9 agonist formulated as a virus-like particle encapsulating a CpG-A oligonucleotide. It was originally developed by Checkmate Pharmaceuticals and is now advanced by Regeneron Pharmaceuticals following its acquisition of Checkmate. The therapy is administered by direct intratumoral injection to activate plasmacytoid dendritic cells and drive a systemic anti-tumor immune response.
In clinical testing, intratumoral vidutolimod has been combined with PD-1 inhibitors including pembrolizumab in patients with advanced melanoma. The combination pairs innate immune activation inside the tumor with systemic checkpoint blockade. Trial NCT02644967 evaluated vidutolimod with pembrolizumab in metastatic melanoma, supporting its positioning alongside innate-agonist plus PD-1 approaches like EIK1001.